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Primary Biliary Cirrhosis (PBC) is considered an autoimmune disease characterized by immune-mediated destruction of the
intrahepatic bile ducts and its characteristic serologic marker, the anti-mitochondrial antibody (AMA). Several factors were
proposed to clarify the pathological and immunological mechanisms of PBC. Immunological reaction with a bacterial or a viral
associationwasidentiﬁedinthepreviousreport,anditseemsprobablethatPBCwasthoughttohavesuchanetiology.Themajority
of patients with PBC was reported to have both RT-PCR and immunohistochemistry evidence of human betaretrovirus infection
in lymph nodes or in 2008, the patient who developed PBC with high HIV viral load had an antiviral therapy and recovered. To
understand the etiology of PBC associated with infection, several factors should be considered and especially animal models may
be useful. In this paper, we introduce three typical animal models of PBC: the dominant-negative form of transforming growth
factor-β receptor type II (dnTGFβRII) mouse, IL-2Rα−/− mouse and NOD.c3c4 mouse, are enumerated and described, and we
discuss previous reports of viral infection associated with PBC and consider the etiology of PBC from our analysis of results in
NOD.c3c4 mouse.
1.Introduction
Primary Biliary Cirrhosis (PBC) is considered an autoim-
mune disease characterized by immune-mediated destruc-
tion of the intrahepatic bile ducts and its characteristic
serologic marker, the anti-mitochondrial antibody (AMA).
AMAisahighlyspeciﬁcautoantibodyfoundinabout90%of
patients with PBC that reacts with an epitope on the E2 sub-
unit of the pyruvate dehydrogenase enzyme complex (PDC-
E2) [1–3]. The epitopes discerned by anti-PDC-E2 and CD4
and CD8 autoreactive T cells are present in the inner lipoyl
domainofPDC-E2.A100-foldincreaseinCD4anda10-fold
increase in CD8 autoreactive T cells inﬁltrate into the portal
tracts [4, 5]. Moreover, several factors were proposed to
clarify the pathological and immunological mechanisms of
PBC. Some biological features of the bile duct cells have been
reported, suggesting a basis for their distinctive destruction
[6–8]. Optionally, soon after autoimmune diseases were ﬁrst
recognizedmorethanacenturyago,immunologicalreaction
with a bacterial or a viral association was identiﬁed and
PBC was thought to have such an etiology (Table 1). [9–
11]. The majority of patients with PBC were reported to
have both RT-PCR and immunohistochemistry evidence of
human betaretrovirus infection in lymph nodes [12], or
in 2008, the patient who developed PBC with high HIV
viral load had an antiviral therapy and recovered [13]. To
determine whether PBC can be induced by infections, ﬁrst
autoimmunity needs to be deﬁned. Autoimmune diseases
occur when a response to a self-antigen involving T cells, B
cells,orautoantibodiesinducesinjurysystemicallyoragainst
as p e c i ﬁ co r g a n[ 14]. Although an autoimmune response
occurs in most persons, it is only in a few persons that
disease actually appears. In PBC, how can infection induce
autoimmunity? The mechanism to explain the association of
infection is molecular mimicry of autoepitops by peptides
of microorganisms. This results in cryptic T-cell epitopes,
the degeneracy of T-cell receptors, and the disruption of
immune tolerance [15, 16]. This is of great signiﬁcance for2 International Journal of Hepatology
Table 1: Viral infections in humans associated with autoimmune
diseases.
Relevance or suspicion of
autoimmune human diseases Representative viruses
PBC HIV-1 p24
MMTV
Multiple sclerosis Epstein-Barrvirus(EBV)Measles
virus
Type1 diabetes
Coxsackie virus B4
Rubella virus
Cytomegalovirus (CMV) Mumps
virus
Rheumatoid arthritis EBV
Hepatitis C virus (HCV)
Systemic lupus erythematosus EBV
Myocarditis Coxsackievirus B3
CMV
Myasthenia gravis Herpes simplex virus
HCV
Guillain-Barre syndrome CMV
EBV
PBC because of the tendency of several viruses to target
particularly the liver. There are several mechanisms by which
viruses are thought to induce an autoimmune response.
These include the expression of some autoantigens, the
expression of major histocompatibility complex molecules,
and changes in cytokine production [16]. To understand
the etiology of PBC associated with infection, several factors
should be considered and especially animal models may be
useful [14, 17]. The association of betaretroviral protein
production and aberrant PDC-E2-like protein expression in
the IL-2Rα−/− mouse and Nonobese diabetic (NOD).c3c4
mouse was reported recently [18].
In this paper, we introduce three typical animal models
ofPBC: thedominant-negative formof transforminggrowth
factor-β receptor type II (dnTGFβRII) mouse, IL-2Rα−/−
mouse, and NOD.c3c4 mouse are enumerated and described
[19–21]. Additionally, we discuss previous reports of viral
infection associated with PBC and consider the etiology of
PBC from our analysis of results in NOD.c3c4 mouse.
2. MurineModel of PBC
2.1. DnTGFβRII Mouse. TGF-β is the most widely distribu-
tedcytokinewithpleiotropiceﬀectsoncellgrowthandimm-
unological controls, speciﬁcallyhaving a promoting eﬀecton
the development of the regulatory T-cell compartment [22].
dnTGFβRII mice were originally developed by Gorelik and
Flavell for the purpose of analyzing the role of this receptor,
which regulates the activation of the T cell function [23].
To disrupt the intracellular domain of the normal receptor
in this mouse, the receptor is incompetent of transduction
afterTGF-β ligation.TheexpressionofdnTGFβRIIislimited
by the CD4 promotor which lacks CD8 silencer, and this
transgenicmousespontaneouslydevelopsfeaturescharacter-
istic of PBC [23]. These features include the expression of
AMA with speciﬁcity against PDC-E2, BCOADC-E2, and
OGDC-E2, as in human PBC. Pathologically, the inﬁltration
of lymphoid cells, especially CD4+ and CD8+ lymphocytes,
in the portal tracts causes biliary duct destruction [19]a n d
the accumulation of natural killer T cells (NKT) in the intra-
hepatic bile duct lesions, resembling the condition found
in human PBC [24]. Although the granuloma formations
around the portal tracts seen in human PBC are not present,
some lymphocytic aggregations like immature granuloma
formation could be observed [25]. Furthermore, the serum
levels of cytokines such as IFN-γ,TNF-α,IL-12p40, and IL-6
are signiﬁcantly increased, as seen in human PBC [26, 27].
2.2. IL-2Rα−/− Mouse. In 2006, Aoki et al. reported a
male child with a genetic deﬁciency of IL-2 receptor αIL-
2Rα,)CD25)expressionwhohadliverdysfunctionwithsero-
logicalexpressionofPBC.Histologically,therewaslymphoid
inﬁltration in the portal tracts and serum antibody to PDC-
E2. The deﬁciency of CD4+ CD25+ subset of regulatory
T cells was considered a key to elucidating of this clinical
condition [20]. Based on these ﬁndings, Wakabayashi et al.
establishedIL-2Rα−/− miceandevaluatedtheirhepaticimm-
unopathology [28]. These mice also show AMA positivity
against PDC-E2 that localizes to the inner lipoyl domain
of the autoantigen. Lymphoid cells, composed of CD4+ and
CD8+ lymphocytes, inﬁltrate into portal tracts without a sig-
niﬁcant increase in NKT. Although mild interface hepatitis
and biliary duct destruction are seen in the liver, granuloma
formations around the portal tracts are not observed [28].
The circulating cytokine proﬁles are similar to those of
dnTGFβRII mice, showing elevations of IFN-γ,TNF-α,IL-
12p40, and IL-6, as identiﬁed in the serum of patients with
PBC [26, 27, 29].
2.3. NOD.c3c4 Mouse. NOD.c3c4 mice were generated by
the introgression of large genetic intervals on chromosome
3 and 4 into a NOD background [21, 30]. NOD and
genetically modiﬁed NOD mice have been reported to
progress to not only spontaneous autoimmune diabetes
but also rheumatoid arthritis, Sjogren’s syndrome, and
thyroiditis [31–34]. NOD.c3c4 mice derived from NOD
strains are considered to be an animal model of PBC with
autoimmune biliary destruction [21, 30]. Most importantly,
these mice show antibodies to PDC-E2. They express AMA
positivity, unlike the dnTGFβR I Im i c ea n dI L - 2 R α−/− mice,
and the rate of positivity has reached 50–60% [35]. Portal
tract inﬁltration with CD3+,C D 4 +, and CD8+ lymphocytes
resultsinchronicnonsuppurativedestructivecholangitisand
epithelioid granuloma formations [21, 30]. However, the
morphological features of the bile ducts lesions diﬀer from
those in human PBC, in which characteristic biliary cyst
formations as well as apparent hepatomegaly are described
[36].International Journal of Hepatology 3
Table 2: Antiviral trials for PBC.
Trial Method Subject Design Primary outcome Year Reference
Pilot studies of single and
combination antiretroviral
therapy
Lamivudine + Zidovu-
dine versus Lamivudine Human
Randomized
controlled
trial (RCT)
Serological improvements
of alkaline phos-phatase,
AST and ALT. Histological
improvement in
necroinﬂammatory score
and a reduction in bile
duct injury.
2004 [43]
Clinical trial: randomized
controlled trial of lamivudine
and zidovudine (Combivir)
Lamivudine + Zidovu-
dine + UDCA versus
UDCA
Human RCT
Serological improvements
in serial alkaline
phosphatase, ALT and
AST.
2008 [44]
Randomized controlled trial of
lamivudine Lamivudine versus UDCA Human RCT O n ec a s es h o w e da
decrease of AMA titers. 2010 [45]
Combination antiretroviral
therapy with Combivir
Lamivudine + Zidovu-
dine versus Placebo
NOD.c3c4
mouse
Histological improvement
in necroinﬂammatory
score and a reduction in
bile duct injury. No
improvement on bile duct
cyst. Decrease in viral
burden.
2007 [46]
Highly active antiretroviral
therapy with reverse trans-
criptase inhibitors and protease
inhibitor
Combination of reverse
transcriptase and protease
inhibitor
NOD.c3c4
mouse
Serological improvements
in alkaline phos-phatase
and AST. Complete
disappearance of
cholangitis.
2008 [47]
3. Possibilityof ViralInfectionAssociated
with PBC
It has been thought that some viruses may associate with
human diseases of oncogenesis or autoimmunity because of
their genome integration or speciﬁc viral-encoding proteins.
Especially, in 1998, Munoz et al. described that there was
an antibody for human immunodeﬁciency virus-1 (HIV-
1) in the serum of PBC patients [37]. To investigate for a
possible immune response to the p24 gag protein of HIV-
1, moderate-to-strong reactivity was found in about 30% of
the patients with Sjogren’s syndrome, as compared with less
than 1% of healthy controls [38], and the 36% of systemic
lupus erythematosus (SLE) patients produced antibodies to
the p24 gag protein [39]. Mason et al. discovered HIV-1
p24 gag protein seroreactivity in 35% of patients with PBC,
29% of patients with SLE, and 39% of patients with either
primary sclerosing cholangitis or biliary atresia, compared
with only 4% of patients with alcohol-related liver disease or
alpha1-antitrypsin-deﬁciency liver disease, and only 4% of
healthy volunteers. Moreover, Western blot reactivity to the
humanintracisternalA-typeparticle(HIAP)proteinsrelated
to HIV-1 was found in 51% of patients with PBC, in 58%
patients with SLE, and in 17% of those with other biliary dis-
eases.Noneofthe23patientswitheitheralcohol-relatedliver
disease or alpha1-antitrypsin deﬁciency and only one of the
healthycontrolsshowedthesamereactivitytoHIAPproteins
[40]. Therefore, these antibody reactivities found in patients
with PBC may be attributable to an immune response to
uncharacterized viral proteins that share antigenic determi-
nants with HIV-1-related retroviruses.
In 2003, a human betaretrovirus clone sequence was
originally detected from the biliary epithelium cDNA library
of a patient with PBC. When searching viral data registered
in BLASTN, the initial partial pol gene fragment was found
to exhibit 95% to 97% identities with mouse mammary
tumor virus (MMTV) and with retrovirus sequences derived
from human breast cancer samples within the overlapping
sequence [12, 41]. Using a speciﬁc MMTV antibody, viral
proteins were shown in the perihepatic lymph nodes but not
inlivertissuesamplesfrompatientswithPBC[41].However,
Selmietal.expressedanopposingviewconcerningthisresult
[42].
Some pilot studies were conducted to determine
whether antiviral therapy impacted the disease progres-
sion (Table 2). First, Mason et al. performed a trial with
reverse-transcriptase inhibitors (lamivudine group versus
lamivudine/zidovudine group) for patients with PBC. The
lamivudine/zidovudine group showed signiﬁcant serological
improvement in the activities of alkaline phosphatase, AST
and ALT, and histological assessment revealed an improve-
ment in the necroinﬂammatory score and a reduction in
bile duct injury compared to the lamivudine group [43].
A further clinical trial was performed with a combination
of lamivudine and zidovudine versus ursodeoxycholic acid
(UDCA). Signiﬁcant diﬀerences were observed in the antivi-
ral therapy versus UDCA with serological improvements in
serial alkaline phosphatase, ALT and AST as well as the
clinical score [44]. Thus, reverse-transcriptase inhibitors are4 International Journal of Hepatology
expected to suppress retroviral proliferation and contribute
to the improvement of PBC. We once investigated the
eﬃcacies of 90 day’s administration of lamivudine to 20 PBC
patients with unsatisfactory biochemical responses to UDCA
in a randomized double blind control trial. As a result, no
signiﬁcant biochemical diﬀerence was seen between both
groups. However, of interest, one case showed a decrease
of AMA titers and biochemical response [45]. These results
were similar to those of studies conducted by Mason et al.
[43]; yet the true eﬃcacy should be evaluated in large-scale
control trials.
4. AreNOD.c3c4 Mice Infected
withaRetrovirus?
NOD.c3c4 mice have been described as a mouse model with
several features similar to PBC [30]. However, these mice
develop marked biliary cyst formation that is not shown
in human PBC. In human PBC, the destruction of chol-
angiocytes leads to ductpenia [48]. When we analyzed the
gene expression of the cholangiocytes of such mice using
microarrayanalysis,therewasconsistentliver-speciﬁcdown-
regulation in the expression of Fas antigen (CD95) [36]. Fas
(CD95) antigen is a member of the tumor necrosis factor
family that binds to Fas ligand (FasL). This gene is situated
at chromosome 19 in mouse [49]. Fas/FasL interactions play
an important role in apoptosis [49–51] .F a si sd e t e c t e di n
hepatocytes and plays an important role in inﬂammation
and cell death in hepatitis virus-infected liver [52]. The Fas
system on cholangiocytes has been also reported in human
and rats, and enhanced expression of FasL on cholangiocytes
has been implicated in progressive bile duct loss in PBC
through apoptosis [53]. Furthermore, FasL expressed by
cholangiocarcinomaswasreportedtoinducelymphocytecell
death and escape immune surveillance [54]. It has been
reported that the Fas/FasL system is strongly associated
with biliary pathological conditions. It was thought that,
because of the downregulation of Fas antigen, the apoptosis
of cholangiocytes cannot easily occur and therefore biliary
cyst formation was found in NOD.c3c4 mice [36]. However,
it was considered that there are also other factors because
the degree of the cyst formation diﬀered according to the
individual though the genetic expression was the same.
In 2007, Chen et al. reported that MMTV gag and
pol gene expression was 4- to 25-fold higher in all three
autoimmune biliary disease models, NOD.c3c4, dnTGF-
βRII, and IL-2Rα−/−, as compared to control mice when
using real-time RT-PCR to quantify MMTV using gag and
pol primers [55]. A randomized study was conducted using
NOD.c3c4 mice treated with a combination therapy of
lamivudine and zidovudine or with placebo (Table 2). Serial
hepatic biochemistry studies showed diminished alkaline
phosphatase in the mice treated with combination therapy.
Histological evaluation showed a signiﬁcant decrease in the
necroinﬂammatory score and the grade of the bile duct
injury in the combination therapy group. However, therapy
had little improvement on bile duct cyst formation. When
compared to mice receiving placebo group, combination
therapy group reduced viral burden measured by the pol
and gag gene RT-PCR [46]. Moreover, Graham et al. treated
NOD.c3c4 mice with combination of reverse transcriptase
inhibitors and protease inhibitor. Hepatic biochemistry
showed signiﬁcant improvements in alkaline phosphatase
and AST, and the cholangitis completely disappeared [47].
Thus, the detection of MMTV in the NOD.c3c4 mice and
resolution of biliary disease with antiviral therapy supports
the retroviral hypothesis for PBC.
However, in order to prove that viral factors are involved
in the pathogenesis of PBC, it is necessary to understand and
elucidate the mechanism of viral replication, reproduction,
the transcription of the virus genomes, the pathogenic roles
of viral tropics, the integrated state, and the interaction
with the host’s immune system, especially the mechanism
by which autoimmune tolerance is broken. Therefore, it is
premature to relate the cause of the clinical condition of PBC
to viral infection based only on the present report. However,
given the unprecedented progress of biotechnology, a more
detailed understanding of these issues can be expected in the
near future.
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